Stay updated on Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page shows a revision label update from v3.6.5 to v3.6.6, indicating a new version of the page was released.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing v3.6.4. This indicates a small deployment update to the page framework, with no changes to the study details or other visible content.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, signaling a minor software update to the page. This update does not affect the study data or the information presented to users.SummaryDifference0.0%

- Check67 days agoChange DetectedThe page now shows Revision: v3.6.3, replacing the previous Revision: v3.6.2, indicating a new release of the page metadata. This is a minor update to the documentation/versioning of the page.SummaryDifference0.0%

- Check74 days agoChange DetectedA new Revision: v3.6.2 appears, replacing Revision: v3.6.0, indicating a small update to the site's version tagging.SummaryDifference0.0%

- Check88 days agoChange DetectedNew help and navigation items were added to the page (No longer looking for participants, How to Read a Study Record, Common Questions, How to Join a Study, Intervention/Treatment) along with a Revision: v3.6.0 tag, and the previous Intervention / Treatment heading and Revision: v3.5.5 tag were removed.SummaryDifference0.5%

Stay in the know with updates to Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Carboplatin/Nab-Paclitaxel + Pembrolizumab in NSCLC Clinical Trial page.